Acadia Pharma (ACAD) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:05 PM EST- Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17
- Full Year 2018 Net Sales Grew to $223.8 Million, a 79% Increase Over Full Year 2017
- Late Stage Pipeline Progressing with Five Clinical Programs Ongoing or Commencing in 2019
- 2019 Guidance: Net Sales $275 Million to $300 Million
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,... More
